XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2017
Dec. 31, 2016
Income Statement [Abstract]    
Net Sales $ 5,054,706 $ 5,238,604
Cost of Sales 1,483,686 1,946,055
Gross Profit 3,571,020 3,292,549
Operating expenses    
Compensation and related expenses 1,698,814 1,247,195
Professional fees 431,326 477,401
Marketing expenses 1,657,158 1,710,357
General and administrative expenses 851,256 1,032,278
Total operating expenses 4,638,554 4,467,231
Operating (Loss) (1,067,534) (1,174,682)
Change in fair value of derivative liability 502,830
Loss on extinguishment of debt (553,222)
Interest (expense) (100,523) (48,611)
Net Income (Loss) (1,218,449) (1,223,293)
Net (loss) income attributable to noncontrolling interests (12,488) (115,749)
Net Income (loss) attributable to Immudyne, Inc. $ (1,205,961) $ (1,107,544)
Basic income (loss) per share attributable to Immudyne, Inc. $ (0.03) $ (0.03)
Diluted income (loss) per share attributable to Immudyne, Inc. $ (0.03) $ (0.03)
Average number of common shares outstanding    
Basic 41,738,101 33,478,229
Diluted 41,738,101 33,478,229